@article{f7bddf0bc6b94ba2bdd95113788fa443,
title = "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury",
abstract = "In response to the recently released 2012 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for acute kidney injury (AKI), the National Kidney Foundation organized a group of US experts in adult and pediatric AKI and critical care nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The first portion of the KDIGO guideline attempts to harmonize earlier consensus definitions and staging criteria for AKI. While the expert panel thought that the KDIGO definition and staging criteria are appropriate for defining the epidemiology of AKI and in the design of clinical trials, the panel concluded that there is insufficient evidence to support their widespread application to clinical care in the United States. The panel generally concurred with the remainder of the KDIGO guidelines that are focused on the prevention and pharmacologic and dialytic management of AKI, although noting the dearth of clinical trial evidence to provide strong evidence-based recommendations and the continued absence of effective therapies beyond hemodynamic optimization and avoidance of nephrotoxins for the prevention and treatment of AKI.",
author = "Palevsky, {Paul M.} and Liu, {Kathleen D.} and Brophy, {Patrick D.} and Chawla, {Lakhmir S.} and Parikh, {Chirag R.} and Thakar, {Charuhas V.} and Tolwani, {Ashita J.} and Waikar, {Sushrut S.} and Weisbord, {Steven D.}",
note = "Funding Information: Financial Disclosure: Dr Chawla has consulted for Abbott Medical, Affymax Medical, Alere Medical, AM Pharma, Astute Medical, Covidien Medical, Gambro Medical, and Sanofi; has received grant support from Eli Lilly , Medical University of South Carolina and UPMC ; has lectured for Nxstage Medical and Gambro; and holds MAKO Corp stock. Dr Liu has received research support from Abbott and CMIC; has served on the Scientific Advisory board for Complexa, the Data and Safety Monitoring Board for Cytopherx, and the Clinical Events Adjudication Committee for Astute; and holds Amgen stock. Dr Palevsky has research support from Spectral Diagnostics and is a consultant for Sanofi, Complexa and Cytopherx. Dr Thakar is a member of the Clinical Events Committee of Cytopherx; is Co-Editor of Springer Nephrology; and has offered clinical trial support to Reata. Dr Tolwani has consulted for Gambro Renal Products and served as an expert panelist for Gambro Renal Products. Dr Waikar is consultant for CVS Caremark, Bio Trends Research Group, and Salix; and has served as expert witness for GE Healthcare, North Star Rx, and Salix. Drs Brophy, Parikh, and Weisbord have no financial relationships with any commercial entity producing health care-related products and/or services.",
year = "2013",
month = may,
doi = "10.1053/j.ajkd.2013.02.349",
language = "English (US)",
volume = "61",
pages = "649--672",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders",
number = "5",
}